Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SIBN

SIBN - SI-BONE Inc Stock Price, Fair Value and News

$16.74-0.29 (-1.70%)
Market Closed

46/100

SIBN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

46/100

SIBN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$15.34

Target 3M

$16.41

Target 6M

$16.04

SIBN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SIBN Price Action

Last 7 days

-1.4%

Last 30 days

-17.0%

Last 90 days

10.5%

Trailing 12 Months

1.1%

SIBN RSI Chart

SIBN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SIBN Valuation

Market Cap

726.4M

Price/Earnings (Trailing)

-33.39

Price/Sales (Trailing)

3.75

Price/Free Cashflow

-68.42

SIBN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$15.34

Target 3M

$16.41

Target 6M

$16.04

SIBN Fundamentals

SIBN Revenue

Revenue (TTM)

193.6M

Rev. Growth (Yr)

20.61%

Rev. Growth (Qtr)

0.05%

SIBN Earnings

Earnings (TTM)

-21.8M

Earnings Growth (Yr)

30.56%

Earnings Growth (Qtr)

25.78%

SIBN Profitability

Return on Equity

-12.64%

Return on Assets

-9.29%

Free Cashflow Yield

-1.46%

SIBN Investor Care

Shares Dilution (1Y)

3.46%

Diluted EPS (TTM)

-0.5

SIBN Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025176.6M185.3M193.6M0
2024144.0M150.7M157.0M167.2M
2023116.7M124.4M132.0M138.9M
202292.1M95.5M99.7M106.4M
202177.0M85.2M87.1M90.2M
202069.1M66.9M71.1M73.4M
201957.7M60.3M63.1M67.3M
201849.8M51.7M53.5M55.4M
201700048.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About SI-BONE Inc

SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
 CEO
 WEBSITEhttps://si-bone.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES357

SI-BONE Inc Frequently Asked Questions

SIBN is the stock ticker symbol of SI-BONE Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of SI-BONE Inc is 726.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SIBN's fair value in chart for subscribers.

The fair value guage provides a quick view whether SIBN is over valued or under valued. Whether SI-BONE Inc is cheap or expensive depends on the assumptions which impact SI-BONE Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SIBN.

As of Wed Jan 28 2026, SIBN's PE ratio (Price to Earnings) is -33.39 and Price to Sales (PS) ratio is 3.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SIBN PE ratio will change depending on the future growth rate expectations of investors.